Report Highlights

U.S. Compounding Chemotherapy: Market Overview

The U.S. compounding chemotherapy market was valued at USD 2.14 billion in 2024 and is forecast to reach USD 3.41 billion by 2032, growing at a 6.0% CAGR. Demand concentrates in hospital oncology units, freestanding infusion centers, and 503B outsourcing facilities that prepare hazardous drugs such as cyclophosphamide, carboplatin, and gemcitabine in batch or patient-specific doses. Hazardous drug handling requirements under USP <800> pushed many hospitals to outsource rather than build negative-pressure compounding suites.

Policy shaped this structure more than commercial dynamics. The Drug Quality and Security Act of 2013 created Section 503B of the Federal Food, Drug, and Cosmetic Act, establishing FDA-registered outsourcing facilities as a distinct channel. Private operators such as QuVa Pharma, SCA Pharmaceuticals, and Leiters Health have led capacity expansion, while government has been dominant in setting quality standards through the FDA and state boards of pharmacy.

Policy-Driven Growth in U.S. Compounding Chemotherapy

The Drug Quality and Security Act of 2013 is the foundational driver. Its Section 503B allows FDA-registered outsourcing facilities to compound sterile drugs in bulk without patient-specific prescriptions, provided they meet current good manufacturing practice under 21 CFR Parts 210 and 211. Oncology groups can therefore buy pre-filled, batch-prepared cytotoxic doses from inspected facilities, shifting volume away from unregistered hospital compounding and expanding addressable demand.

USP General Chapter <800>, Hazardous Drugs—Handling in Healthcare Settings, took effect on December 1, 2019, requiring closed-system transfer devices and dedicated containment. State boards of pharmacy incorporate it into licensing rules, pushing hospitals toward outsourced preparation. Medicare Part B pays chemotherapy at average sales price plus 6 percent under Section 1847A of the Social Security Act, sustaining outpatient infusion volumes that feed compounder demand.

Regulatory Barriers and Compliance Costs

The most binding barrier is registration and inspection under Section 503B, administered by the FDA's Office of Pharmaceutical Quality. Outsourcing facilities must pay an annual establishment fee, undergo unannounced inspections, and report adverse events, with deficiencies issued as Form 483 observations. A new facility typically requires 12 to 18 months of build-out, cleanroom validation, and registration before it can ship product.

USP General Chapter <797>, Pharmaceutical Compounding—Sterile Preparations, revised with an effective date of November 1, 2023, tightened beyond-use dating, environmental monitoring, and personnel gowning requirements. Pharmacies must upgrade ISO Class 5 primary engineering controls, often requiring capital expenditure in the hundreds of thousands of dollars per suite. State boards enforce these standards during licensure inspections, and OSHA enforces worker exposure controls under 29 CFR 1910.1200.

Policy-Created Opportunities in the U.S.

The CMS Innovation Center's Enhancing Oncology Model, launched July 1, 2023 and running through 2030, pays participating practices for chemotherapy episodes and rewards lower drug spend. Batch compounding under 503B reduces waste from partial vials, giving EOM practices a financial incentive to contract with registered outsourcing facilities and creating a measurable procurement channel.

FDA's drug shortage framework under Section 506E of the Federal Food, Drug, and Cosmetic Act allows outsourcing facilities to address listed shortages affecting platinum agents such as cisplatin and carboplatin. Compounders that secure registration and quality systems for these products ahead of shortage listings can capture contract volume from health systems facing supply interruptions.

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013 (Public Law 113-54), administered by the U.S. Food and Drug Administration. Outsourcing facilities must register, comply with current good manufacturing practice, submit adverse event reports, and maintain product traceability under Title II, the Drug Supply Chain Security Act, whose enhanced electronic interoperability requirements took effect November 27, 2024.

State boards of pharmacy license 503A pharmacies and enforce USP <797> and <800> through inspections, while OSHA governs cytotoxic exposure under its Hazard Communication Standard. Enforcement of the revised USP <797> standards is expected to tighten at state boards through 2026. Compared with Canada, where provincial colleges license compounding without a federal outsourcing category, and the EU, where Directive 2001/83/EC leaves magistral preparations to national rules, the U.S. framework is more prescriptive.

Long-Term Policy Outlook for U.S. Compounding Chemotherapy

By 2032, the DQSA framework will remain intact while FDA enforcement shifts toward risk-based inspection of 503B facilities, with more frequent unannounced visits to sites carrying repeat Form 483 observations. Facilities with clean inspection records will win contract share from health systems, while warning-letter recipients will exit or sell, accelerating consolidation among mid-sized outsourcing operators.

Drug pricing reform will reshape margins. Medicare Part B drug price negotiation under the Inflation Reduction Act of 2022 begins with prices effective in 2028, pressuring the average sales price baseline that compounders and their hospital customers use for reimbursement modelling. The Enhancing Oncology Model's 2030 end date will force a successor design, likely rewarding documented waste reduction.